Inhaled ciclesonide for preventing lung disease in preterm infants
Inhaled ciclesonide - a phase I study in preterm infants
This study is looking at whether inhaled ciclesonide can help prevent lung problems in premature babies born before 30 weeks, while being safer than other treatments, so that these little ones can have a better chance at healthy development.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Mercy Hosp (Kansas City, Mo) NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10995821 on NIH RePORTER |
What this research studies
This research investigates the use of inhaled ciclesonide, a medication that may help prevent bronchopulmonary dysplasia (BPD) in preterm infants born before 30 weeks of gestation. The study aims to determine if ciclesonide can effectively reduce the risk of BPD without causing serious side effects that are associated with other treatments like dexamethasone. By focusing on the safety and efficacy of this inhaled therapy, the research seeks to provide a better treatment option for vulnerable infants. Participants will be closely monitored to assess the medication's impact on lung health and overall development.
Who could benefit from this research
Good fit: Ideal candidates for this research are preterm infants born before 30 weeks of gestation who are at risk of developing bronchopulmonary dysplasia.
Not a fit: Patients who are not preterm or those who do not have a risk of developing bronchopulmonary dysplasia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for preventing lung disease in preterm infants.
How similar studies have performed: Previous research has shown that inhaled therapies can be effective in treating lung conditions in older children, but this specific approach with ciclesonide in preterm infants is novel.
Where this research is happening
Kansas City, United States
- Children's Mercy Hosp (Kansas City, Mo) — Kansas City, United States (Active)
Researchers
- Principal investigator: Sampath, Venkatesh — Children's Mercy Hosp (Kansas City, Mo)
- Study coordinator: Sampath, Venkatesh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.